Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581124 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02581124: Completed Phase 1 study, sponsored by Akros Pharma.
NCT02581124 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02581124, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP) inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and tolerability of JTZ-951 when administered alone and one hour after the administration of lapatinib.
Interventions
- DRUG Lapatinib
- DRUG JTZ-951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02581124 record still lists
NCT02581124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Lapatinib is the first listed.
NCT02581124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02581124 about?
NCT02581124 is a clinical study titled "Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease". Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP) inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and tolerability of JTZ-951 when administered alone and one hour after the administration of lapatinib.
What is the current status of trial NCT02581124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02581124?
The interventions under investigation include: Lapatinib (DRUG), JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT02581124?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02581124's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia